

April 28, 2021

Chairs Bernardy, Tomassoni and Members of the Higher Education Conference Committee:

Regenerative Medicine Minnesota (RMM) aspires to improve the health of Minnesotans by supporting and advancing regenerative medicine research, industry, and innovative health care delivery to patients. This statewide initiative also opens new economic opportunities through commercialization of technologies and new jobs in the biomedical sector.

Regenerative Medicine Minnesota leverages the strengths of Minnesota institutions to position the state at the forefront of regenerative medicine. Since its inception in 2014 RMM has funded innovative projects that advance health and support the biotechnology industry in areas such as cardiovascular disease, cancer, diabetes, kidney disease, eye disease, musculoskeletal disorders, obesity, spinal cord injury, and neurodegenerative disorders. These conditions are particularly common in afflicting Minnesotans.

Of the \$4.35 million RMM receives annually, \$3 million is invested in funding new, innovative research while the majority of the remaining funds fuels commercialization of these novel technologies by the Minnesota biobusiness community. As one example, Dr. Robert Tranquillo and Senior Research Associate, Zeeshan Syedain developed biologically-engineered "off-the-shelf" vascular grafts (heart bypass), heart valves (congenital heart defect), and vein valves (chronic venous insufficiency/leg ulcers). These tissues, produced by skin cells (fibroblasts), have the capacity to grow and may thus transform the treatment of pediatric congenital heart defects.

We urge the committee to adopt the House position and maintain full funding to ensure uninterrupted advances in regenerative medicine throughout Minnesota. Continuous and adequate funding is essential to preserve Minnesota as a leader in regenerative medicine and maintain competitiveness, as other states further fund regenerative medicine.

Research in regenerative medicine is the future to discovering new ways to treat chronic, debilitating diseases for which curative therapies are currently lacking. With support from the state of Minnesota RMM will continue to be at the forefront of discovery and translation of innovative solutions, paying great dividends to the citizens of our state for many years to come.

Shernan Holtan, MD University of Minnesota Andre Terzic, MD, PhD, FAHA

Mayo Clinic

Co-chairs Regenerative Medicine Minnesota Funding Board

Kristina Bloomquist, MEd, CPHQ, CHRC

National Marrow Donor Program

Kistina Bloomguit

David Knapp, PhD Boston Scientific

Vil Kung

Barbara Nelsen, PhD, MBA

Nelsen Biomedical